Compare Immunovant Inc. Common Stock (IMVT) vs Progressive Corp (PGR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Immunovant Inc. Common Stock vs Progressive Corp — how do they compare? Immunovant Inc. Common Stock trades at $30.01 (market cap $6.62B), while Progressive Corp trades at $218.73 (market cap $124.28B). The key difference: Progressive Corp is far larger — about 18.8× Immunovant Inc. Common Stock's market cap, and Progressive Corp pays a 0.19% dividend while Immunovant Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Immunovant Inc. Common Stock for 0 Days and Progressive Corp for 81 Days on average.
| IMVT | PGR | |
|---|---|---|
Market Cap | $6.62B | $124.28B |
Volume | 1,131,364 | 2,551,191 |
Sector | Health | Financials |
52-Week High | $44.96 | $242.16 |
52-Week Low | $17.03 | $190.40 |
Typical Hold Time | 0 Days | 81 Days |
Enterprise Value | $5.72B | $132.48B |
Dividend Yield | — | 0.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
PGR trades at $218.73, up 3.15% today, with a bullish technical signal from moving averages and strong fundamentals including a 12.85% net income margin and 34.94% ROE. Revenue grew from $49.6B in 2022 to $87.6B in 2025, with net income surging to $11.3B. The company recently announced a $0.10 dividend payable in October 2026, and Q2 2026 earnings beat expectations.
The outlook is positive given robust earnings growth and analyst consensus price target of $222.23, though risks include intensifying competition in personal auto insurance and potential market volatility. Institutional interest remains strong with recent position increases by funds like QRG Capital Management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Immunovant Inc. Common Stock
Immunovant is a clinical-stage immunology company developing therapies for autoimmune diseases. Its pipeline includes anti-FcRn antibody candidates designed for subcutaneous administration.
Read more on IMVT →About Progressive Corp
Progressive underwrites private and commercial auto insurance and specialty lines
Read more on PGR →
